Live Feeds
● LIVE Updated 1h ago · 19 sources tracked

Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?

Eli Lilly and the FDA provided an unnamed 79-year-old man exclusive access to the unapproved obesity drug retatrutide in April 2026. The access was granted via a compassionate use program. This has led to public speculation and government inquiries regarding the patient's identity.

RSS Source map (15)

What changed

Recent reports reveal the White House denied the patient is President Donald Trump.

Live updates

  1. Eli Lilly Granted Exclusive Access to Obesity Drug for Unidentified 79-Year-Old

    Eli Lilly and the FDA provided an unnamed 79-year-old man exclusive access to the unapproved obesity drug retatrutide in April 2026. The access was granted via a compassionate use program. This has led to public speculation and government inquiries regarding the patient's identity.

    What's confirmed:

    • Eli Lilly provided an unidentified 79-year-old man exclusive access to the experimental obesity drug retatrutide.
    • The drug was provided via a compassionate use program.
    • The FDA and Eli Lilly granted this access in April 2026.
    • Senator Maggie Hassan requested documents from HHS Secretary Kennedy regarding the access.
    • The White House denied that the application was filed for President Donald Trump.

    Still unconfirmed:

    • The mystery patient is President Donald Trump.
    • The patient is a well connected man.
    confidence 90%